Market revenue in 2023 | USD 34.6 million |
Market revenue in 2030 | USD 62.3 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Fish |
Fastest growing segment | CISH |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | FISH, CISH |
Key market players worldwide | Thermo Fisher Scientific Inc, Abbott Laboratories, Agilent Technologies Inc, Merck KGaA, Bio-Rad Laboratories Inc, Bio View Ltd, Revvity Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to in situ hybridization market will help companies and investors design strategic landscapes.
Fish was the largest segment with a revenue share of 52.89% in 2023. Horizon Databook has segmented the Australia in situ hybridization market based on fish, cish covering the revenue growth of each sub-segment from 2018 to 2030.
Australia in situ hybridization market is expected to witness rapid growth over the forecast period due to increasing burden of cancer and high prevalence of inherited diseases. According to Australian government’s Department of Health, about 2 million people in Australia are suffering from rare diseases, 80% of which are genetic.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia in situ hybridization market , including forecasts for subscribers. This country databook contains high-level insights into Australia in situ hybridization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account